AbbVie's Allergan Aesthetics Reinforces Scientific Leadership With 21 Evidence-Based E-Posters Across Full Aesthetics Portfolio At AMWC 2026
AbbVie, Inc. ABBV | 0.00 |
- Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines (as early as 8 hours), robust and consistent efficacy, and a favorable safety profile across global patient populations
- Real-world and clinical data reinforce onabotulinumtoxinA (BOTOX® Cosmetic) as a foundation for high patient satisfaction, natural-looking results, and the gateway to multimodal facial aesthetic treatment plans
- Portfolio-wide results demonstrate continued investment in innovative, integrated approaches for patients and practitioners
